Cartesian Therapeutics Inc.
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | 100.0% | |
| 198.5% | 1.5% | 3.1% | 0.6% | 73.9% | – | – | – | 2,831.2% | – | – | – | – | |
| -98.5% | 100.0% | 100.0% | 100.0% | 100.0% | – | 100.0% | 100.0% | -2,731.2% | 100.0% | 100.0% | – | – | |
| 198.5% | 271.4% | 166.7% | 37.9% | 2,945.7% | – | 1,334.0% | 4,989.6% | 3,053.5% | 1,551.1% | 24,952.6% | – | 4,630.0% | |
| 86.2% | 268.2% | 161.8% | 21.0% | 1,695.6% | – | 755.9% | 2,429.5% | 1,458.0% | 865.6% | 9,120.5% | – | 2,073.5% | |
| 101.0% | 539.5% | 328.6% | 58.9% | 4,641.3% | – | 2,089.9% | 7,419.1% | 1,929.4% | 2,416.7% | 34,073.1% | – | 5,913.3% | |
| -199.4% | -439.5% | -228.6% | 41.1% | -4,541.3% | – | -1,989.9% | -7,319.1% | -4,660.6% | -2,316.7% | -33,973.1% | – | -6,679.7% | |
| 19.4% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | 0.0% | – | – | – | – | – | |
| -137.4% | -2,379.1% | -973.0% | 41.4% | -6,248.8% | – | -1,610.0% | 5,330.9% | -7,942.9% | -10,746.5% | -50,233.3% | – | -10,906.2% | |
| 23.3% | -229.9% | 2.4% | 0.4% | – | – | – | – | – | -970.7% | – | – | – | |
| -137.4% | -2,149.3% | -973.0% | 41.4% | -6,248.8% | – | -1,610.0% | 5,330.9% | -7,942.9% | -9,775.7% | -50,233.3% | – | -10,422.5% | |
| -115.1% | -2,375.8% | -969.9% | 42.0% | -6,174.9% | – | -1,504.9% | 5,528.5% | -7,808.8% | -10,682.3% | -49,444.9% | – | -10,670.5% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.